Serum Amyloid A Protein And Fetuin A Levels

NCT02433405 | Completed

• 1 other identifier: SAAFA1
• Study Type: observational
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study was to evaluate acute phase proteins (APPs) Fetuin-A and Serum Amyloid A (SAA) levels in gingival crevicular fluid (GCF) and serum samples in periodontal health and disease.

Conditions

Periodontal Diseases

Keywords

Serum Amyloid A; Fetuin-A; gingival crevicular fluid; serum; periodontal diseases

Outcome Measures

Primary Outcomes (1)

• Serum Amyloid A (SAA) levels as an inflammatory marker in periodontal disease both in serum and GCF

  Day 0

Secondary Outcomes (1)

• Fetuin-A levels as an inflammatory marker in periodontal disease both in serum and GCF

  Day 0

Study Arms (3)

Group 1

Chronic Periodontitis-serum amyloid A, Fetuin-A

Biological: Fetuin-A; Biological: Serum Amyloid A

Group 2

Plaque induced Gingivitis-serum amyloid A, Fetuin-A

Biological: Fetuin-A; Biological: Serum Amyloid A

Group 3

Control Group-serum amyloid A, Fetuin-A

Biological: Fetuin-A; Biological: Serum Amyloid A

Interventions

Fetuin-A BIOLOGICAL

Acute phase protein

Group 1; Group 2; Group 3

Serum Amyloid A BIOLOGICAL

Acute phase protein

Group 1; Group 2; Group 3

Eligibility Criteria

• Age: 28 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

The study population consisted totally 60 subjects whose age (28-45) and sex (33 men, 27 female) were matched.

You may qualify if:

• GI\>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically.
• Systematically healthy patients
• No alveolar bone and attachment loss
• Inflammation signs such as redness, edema and increased BOP levels,
• GI≥2, PPD≤3mm, CAL≤3mm.
• Systematically healthy patients
• No bone and attachment loss,
• GI=0, PPD≤3mm, CAL≤3mm
• Systematically healthy patients

You may not qualify if:

• Aggressive Periodontitis,
• Oral pathologies,
• Patients with any other systemic diseases,
• Pregnant women and those in the lactation period,
• Patients with smoking habit and taking medication
• Patients received periodontal therapy in last 6 months

Sponsors & Collaborators

• Bulent Ecevit University: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Gingival crevicular fluid and Serum

MeSH Terms

Conditions

Periodontal Diseases

Interventions

alpha-2-HS-Glycoprotein; Serum Amyloid A Protein

Condition Hierarchy (Ancestors)

Mouth Diseases; Stomatognathic Diseases

Intervention Hierarchy (Ancestors)

Glycoproteins; Glycoconjugates; Carbohydrates; Fetuins; Alpha-Globulins; Serum Globulins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Calcium-Binding Proteins; Carrier Proteins; Cystatins; Globulins; Amyloidogenic Proteins; Amyloid; Acute-Phase Proteins

Study Officials

• ÇİĞDEM COŞKUN TÜRER, PhD

  BULENT ECEVIT UNIVERSITY FACULTY OF DENTISTRY DEPARTMENT OF PERIODONTOLOGY

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr.

Study Record Dates

• First Submitted: April 24, 2015
• First Posted: May 5, 2015
• Study Start: December 1, 2013
• Primary Completion: April 1, 2014
• Study Completion: November 1, 2014
• Last Updated: May 5, 2015

Record last verified: 2015-04